2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”) |
|
|
| Not yet recruiting | 2 | 150 | Europe | Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride | Viracta Therapeutics, Inc., Viracta Therapeutics, Inc. | Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04] | | | | |
NCT06474442: A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis |
|
|
| Not yet recruiting | 2 | 40 | RoW | BD111 Injection (investigational new drug), BD111 Lentivirus-like particles, also called HSV-1-erasing lentiviral particles (HELP), Triple-drugs therapy of HSV-1 stromal keratitis, Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops | Shanghai BDgene Co., Ltd. | Herpes Simplex Virus Type I Stromal Keratitis | 12/25 | 12/26 | | |
